PXS will never get back to its previous highs as they have given away the upside potential in return for a collaboration model which will never see them exposed again to huge cash demand of commercialisation. They can be very successful with model but it probably has a limit to the upside. It's a different, more prudent company now.
Pharmaxis and Novogen to present at Australian Biotech Invest, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
